Compare SPCE & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | FLGT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.5M | 511.0M |
| IPO Year | 2017 | 2016 |
| Metric | SPCE | FLGT |
|---|---|---|
| Price | $2.47 | $20.11 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $3.51 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 242.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,544,000.00 | ★ $18,730,000.00 |
| Revenue This Year | N/A | $2.80 |
| Revenue Next Year | $22,960.98 | $15.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $13.46 |
| 52 Week High | $8.90 | $31.04 |
| Indicator | SPCE | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 43.15 |
| Support Level | $2.38 | $19.35 |
| Resistance Level | $2.68 | $21.56 |
| Average True Range (ATR) | 0.13 | 0.91 |
| MACD | -0.04 | -0.19 |
| Stochastic Oscillator | 17.20 | 21.52 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.